Sonic Hedgehog (Shh) signaling regulates mesenchymal proliferation and differentiation during embryonic lung development. In the adult lung, Shh signaling maintains mesenchymal quiescence and is dysregulated in diseases such as idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease. Our previous data implicated a role for Shh in postnatal lung development. Here, we report a detailed analysis of Shh signaling during murine postnatal lung development. We show that Shh pathway expression and activity during alveolarization (postnatal day [P] 0-P14) are distinct from those during maturation (P14-P24). This biphasic pattern is paralleled by the transient presence of Gli1 1 ;a-smooth muscle actin (a-SMA) 1 myofibroblasts in the growing alveolar septal tips. Carefully timed inhibition of Hedgehog (Hh) signaling during alveolarization defined mechanisms by which Shh influences the mesenchymal compartment. First, interruption of Hh signaling at earlier time points results in increased lung compliance and wall structure defects of increasing severity, ranging from moderately enlarged alveolar airspaces to markedly enlarged airspaces and fewer secondary septa. Second, Shh signaling is required for myofibroblast differentiation: Hh inhibition during early alveolarization almost completely eliminates Gli1 1 ;a-SMA 1 cells at the septal tips, and Gli1-lineage tracing revealed that Gli1 1 cells do not undergo apoptosis after Hh inhibition but remain in the alveolar septa and are unable to express a-SMA. Third, Shh signaling is vital to mesenchymal proliferation during alveolarization, as Hh inhibition decreased proliferation of Gli1 1 cells and their progeny. Our study establishes Shh as a new alveolarization-promoting factor that might be affected in perinatal lung diseases that are associated with impaired alveolarization.
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Clinical Relevance
Sonic Hedgehog (Shh) signaling controls embryonic mesenchyme and is dysregulated in adult lung diseases with altered mesenchymal function, such as idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease. To determine whether and how Shh regulates the mesenchyme during postnatal lung development, we carried out a detailed temporal-spatial analysis of Shh signaling pathway expression and activity, and characterization of cell types involved during alveolarization and maturation phase. We detect temporally distinct structural defects altering lung compliance caused by Shh inhibition during secondary septum formation and uncover Shh-induced myofibroblast differentiation and proliferation of Gli1 1 mesenchymal cells as two key components of normal postnatal lung development. Our study establishes Shh as a new alveolarization-promoting factor that might play a role in perinatal lung injury.
Though most lung structures are generated during embryonic lung development, the resulting saccular lung requires the final alveolar stage of development (1) . The two phases of the alveolar stage, alveolarization and maturation, expand the alveolar surface and thin the air-blood interface (2) . During alveolarization (z postnatal day [P]0-P14 in rodents), secondary septa form, thereby dividing the lung into an intricate structure of connected alveoli and ducts. The balanced deposition of collagen, elastin, and proteoglycans promotes structural support and elasticity of the growing septa, and is key to the lung's mechanical properties (3) . One of the cellular septum components, the myofibroblasts, produce matrix and exert contractile forces that counteract respiration-induced lung stretching (4) . During maturation (zP14-28 in rodents), the secondary alveolar septa become thinner as the mesenchymal cell number decreases (5, 6) , and the initial double capillary layer fuses to a single layer (2) . Perinatal and early postnatal injury profoundly affect these processes, as seen in the clinical syndrome of bronchopulmonary dysplasia (7) . Defining the pathways that instruct epithelial and mesenchymal cells during these phases will provide insight into the underlying mechanisms of developmental lung disease. Important roles for mesenchyme-associated signaling pathways, such as platelet-derived growth factor (PDGF), fibroblast growth factor (FGF), and transforming growth factor (TGF), have been described in animal models of alveolar septation (8) . Though no role for Sonic Hedgehog (Shh) signaling has been discovered, it is an excellent candidate pathway, because it communicates from lung epithelium to mesenchyme during embryonic development, contributing to the balanced proliferation and differentiation of mesenchyme essential for branching morphogenesis, and is active in the postnatal phase (9) . We thus hypothesized that Shh is necessary for alveolarization and maturation of the postnatal lung.
Shh is a morphogen that regulates organogenesis of the lung and other organs (10) . Canonical Hedgehog (Hh) pathway activity entails binding of Hh ligand to its receptor, Patched 1 (Ptch1), followed by release of Ptch1-mediated inhibition of Smoothened (Smo), leading to post-translational activation of the transcription factors, Gli2 and Gli3, and downstream transcription of target genes, including Gli1, Ptch1, and Hhip (9). Gli1 expression, though not required for Hh signaling in most contexts, provides positive feedback and serves as a useful reporter of active Hh signaling, because Gli1 is a direct downstream target (11) . Ptch1 and Hh-inhibitory protein (HHIP), on the other hand, contribute to negativefeedback loops: Ptch1 inhibits Smo and internalizes Shh for degradation; HHIP inhibits Shh by competing with Ptch1 at the cell surface. Polymorphisms in HHIP are linked to increased susceptibility to asthma and chronic obstructive pulmonary disease (12) (13) (14) .
Shh is released from lung epithelium and signals to the mesenchyme. Shh germline knockout results in hypoplastic lungs with defective branching and decreased mesenchyme (15) (16) (17) . The absence of a-smooth muscle actin (a-SMA) 1 cells in the bronchial walls of Shh knockout mice suggests that absent Shh affects cells that normally differentiate into bronchial smooth muscle cells and myofibroblasts. Mesothelial cell movement into the lung is decreased in mice with mesothelium-restricted loss of Hh signaling (18) . Fate mapping of Gli1 1 cells from embryonic day [E] 12.5 shows that they give rise to myofibroblasts at the septal tips (19) . These findings suggest that Shh signaling is required for mesenchymal cell differentiation into myofibroblasts and smooth muscle cells, but the postnatal role of Shh is not well defined.
Shh and Ptch1 mRNA are present in lung at birth (15) and Shh protein is detected until P15 (17) . Up-regulation of Shh and Ptch1 expression after hyperoxiainduced lung injury in neonatal rats raises the possibility that Hh signaling might play a role in bronchopulmonary dysplasia (20 mice were cross-bred with R26R tdTom to generate double-heterozygous mutants. Genotyping was done as previously described (21) . C57BL/6J and R26R tdTom mice were from Jackson Laboratories (Bar Harbor, ME).
For Hh inhibition experiments, neonatal animals were injected subcutaneously with 30 mg/kg of pan-Hh antibody 5E1 (ImmunePrecise, Victoria, BC, Canada) (27) or IgG isotype control (Lampire, Pipersville, PA) at P1, P3, P5, or P7. To activate Cre-recombinase for lineage-tracing experiments, mice received tamoxifen (250 mg/g) or corn oil subcutaneously at P1. Recombination of tdTom was detected at P3 in tails by immunofluorescence (IF) microscopy. Recombined animals received one subcutaneous dose of 5E1 or IgG.
Lung Histology and Morphometry
Animals were killed using pentobarbital (120 mg/kg) at indicated time points. For IF-based localization studies and 5-bromo-4-chloro-3-indolyl-b-D-galactopyranoside (X-gal) staining, lungs were fixed with 4% paraformaldehyde and optimal cutting temperature (OCT) medium embedded (21) . For morphometric analysis, the lungs were inflated with 4% paraformaldehyde at 25 cm H 2 O (21). Hematoxylin and eosin-stained lung sections (5 mm) were analyzed, blinded to treatment group and sample number. At least 10 random fields of the alveolar compartment were analyzed, including both right and left lung, using a Nikon Ni epifluorescence microscope and Nikon NIS-Elements software (Nikon, Melville, NY). To assess the alveolar airspace, the mean linear intercept (MLI) was measured (21) . To assess secondary septum formation, we measured the alveolar septal tip count, calculated by dividing the number of septal tips per image by the number of complete alveolar spaces per image (see Figure E3D in the online supplement). We used Picrosirius red, Resourcin-Fuchsin and periodic acid-Schiff-Alcian blue staining to detect collagen, elastin, and proteoglycans, respectively.
Pressure-Volume Curves
Lung volumes were measured at different pressures through ex vivo inflation with PBS, following Shifren's protocol with minor modifications (see the online supplement) (28) .
Lung Elastin, OH-Proline, and Total Protein Content
Lung elastin, OH-proline and total protein content were measured as described previously (28) .
IF Staining
OCT-frozen lung sections (5 mm) were stained with primary and IF-labeled secondary antibodies (see the online supplement) (21) . Terminal deoxynucleotidyl transferase dUTP nick end labeling staining was done per the manufacturer's recommendations (Roche, Indianapolis, IN). IF-based colocalization quantification was performed on high-, medium-, and low-power images using an Ni epifluorescence microscope and Nikon NIS-Elements software (21) , as well as a Vectra3 multispectral-imaging system (PerkinElmer, Waltham, MA) and InForm software (Chicago, IL).
Quantitative RT-PCR
Total RNA extraction from lung, reverse transcription and quantitative RT-PCR (qRT-PCR) were performed following standard protocols (see the online supplement). qRT-PCR was performed using a Step-One-Plus instrument (Applied Biosystems, Waltham, MA) and the Quantifast SYBR-green mix (Qiagen, Germantown, MD). Assays were normalized to Gapdh and Hprt, and relative gene expression was calculated by the 2 -D(DCT) method. Gene expression changes were considered significant if the Student's t test indicated a P value less than 0.05 in both Gapdh-and Hprtnormalized samples.
Statistical Analysis
Data are presented as mean (6SD). Student's t test was used for statistical analysis, with P less than 0.05 considered significant.
Results

Shh Pathway Expression and Activity during Alveolarization and Maturation
We first established the temporal relationship between Hh pathway genes and structural processes during secondary septum formation and maturation. Therefore, we measured mRNA expression of Shh, Gli1, Ptch1, and Hhip in C57BL/6J mice, and assessed Hh pathway activity in Gli1 nlacZ reporter mice (22) . These data were related to morphometric and cell proliferation measurements (Figure 1 ). There is a marked increase in the expression of Shh, Gli1, and Ptch1 by P2. Shh expression peaks between P2 and P14. Similarly, expression of the direct transcriptional target Gli1 peaks between P2 and P10, whereas Ptch1 and Hhip show more modest changes and remain elevated until P18 ( Figures 1A and 1B) . In Gli1 nlacZ/1 reporter mice, the fraction of Gli1 1 cells in the alveolar area decreases after birth to approximately 11% at P2, and thereafter increases to 30-32% at the peak around P8-P10 ( Figure 1C ). We also examined the spatial distribution of Gli1-expressing cells throughout the postnatal period ( Figure E1 ). At P0, Gli1 1 cells are localized around the airways and in primary septa. After a nadir of several days, in which Gli1 1 cells are mostly located in peribronchial and perivascular locations, increased numbers of Gli1 1 cells appear in the alveolar septa, including the tips, peaking around P8-P10 and declining thereafter, whereas peribronchial and perivascular Gli1 1 cells remain constant. MLI measurements document the underlying process of alveolarization between P3 and P9 ( Figure 1D ). Beyond P9, the MLI stabilizes, consistent with reports that, during lung maturation, the number and size of alveoli do not change significantly (29) . The data reveal a biphasic pattern, where Shh signaling and expression is high during alveolarization and falls during maturation.
Given the proliferative effect of Shh signaling, we assessed cell proliferation in the alveolar compartment. The percentage of proliferating (Ki67 1 ) cells increases from approximately 6% at P2 to approximately 18% at P6, and declines to approximately 5% at P14 ( Figure 1E ). We also measured proliferative indexes of cells positive or negative for reporters of Shh and Gli1 expression (Shh nlacZ and Gli1 nlacZ mice; Figure 1F ). Gli1 1 cell proliferation peaks during alveolarization at P6, whereas proliferation of Shh 1 cells, which are Gli1 2 and should be unresponsive to Hh ligand, remains at similar levels from P2 to P6 and then declines. The magnitude of the proliferation index of Gli1 1 cells indicates that they are a prominent component of the mesenchymal cell expansion during alveolarization (30) .
Characterization of Cells Expressing Shh or Gli1 during Postnatal Lung Development
A large body of evidence supports the strict dichotomy between Shh-expressing epithelial cells and Ptch1-expressing mesenchymal cells during embryonic lung development (9, 31) . To identify the cell types involved in Shh signaling in postnatal lung, and to confirm the persistence of this dichotomy in the postnatal period, we characterized Shh-and Gli1-expressing cells in appropriate reporter mice based on IF costaining with cell-specific markers and anatomic location (see summary in Table  E1 ). Fluorescent cells were analyzed in both the peribronchial and the alveolar compartment. ORIGINAL RESEARCH (Figure 2A, c) . Shh 1 cells do not express the mesenchymal markers, a-SMA (Figure 2A , e) and collagen-1 ( Figure E2A,  b) , the endothelial marker, CD31 ( Figure  E2A, c) , or the hematopoietic marker CD45 (data not shown).
We also examined Gli1 1 cells ( Figures  2B and 2C ). In the peribronchial areas, most Gli1 1 cells are negative for the fibroblast marker, collagen-1 ( Figure 2B, a) , in contrast to adult lung (21) . Conversely, in the alveolar compartment, almost all Figure 5C ).
Given the requirement of PDGFRa 1 fibroblasts for secondary septum formation (32), we also examined colocalization of PDGFRa with Gli1, and found that 20-25% of peribronchial and 10-15% of alveolar Gli1 1 cells also express PDGF receptor a (PDGFRa) ( Figure 2B, g and i) . Overall, these results indicate that Gli1 1 cells in the alveolar compartment are interstitial fibroblasts and myofibroblasts, consistent with lineage-tracing experiments for myofibroblasts (19) . In contrast, most peribronchial and perivascular Gli1 
Inhibition of Hh Signaling during Alveolarization Affects Secondary Septum Initiation and Lung Compliance
We previously shown that Hedgehog (Hh) pathway inhibition at P3 with the anti-Hh monoclonal antibody, 5E1, causes increased MLI (21) Figure E3A ). These data confirm that 5E1 blocks canonical Hh pathway activity and does not affect epithelial Shh expression.
We examined lung structure after Hh inhibition. A time course experiment shows that Hh inhibition initiated at P3 affects lung morphology as early as P6 ( Figure E3B ). Morphometric assessment was conducted on P6 and P8 lungs. To determine whether there is a decrease in numbers of secondary septa formed, we measured the alveolar septal tip count, defined as the ratio of the number of alveolar septal tips to the number of alveolar air spaces ( Figure E3D ). Hh blockade at P1 decreases the septal tip count by approximately 20%, along with increasing the MLI, at P6 and P8 ( Figures 3A and 3B ), indicating that Hh inhibition impaired septum initiation or, less likely, resulted in destruction of newly formed septa. In contrast, Hh inhibition at P3 increases MLI, but does not alter septal tip count at P6 and P8 ( Figures 3A and 3B) , suggesting that the critical Shh signaling period for alveolar septum initiation is before P3. We further tested at which time point Hh inhibition no longer affects MLI. We found that Hh inhibition at P5 results in subsequent increased MLI, but inhibition at P7 does not ( Figure E3C ). To test whether the MLI increase after Hh inhibition at P3 could at least in part be due to decreased compliance and increased size of the lung when inflated at 25 cm H 2 O pressure, we measured wet lung weight and lung volume at different inflation pressures ex vivo in 5E1-and IgG-treated lungs at P8 ( Figure 3C ). Wet lung weights and body weights were not different between the treatment groups. In contrast, the pressure-volume curves show 16-24% increased lung volumes in Hhinhibited lungs at inflation pressures of 15-25 cm H 2 O.
Inhibition of Hh Signaling Alters Gene Expression of Structurally Important Extracellular Matrix and Intracellular Molecules
In liquid-inflated lungs, compliance is a function of extracellular matrix (ECM) components, such as elastin, collagen, proteoglycans, and (probably to a lesser extent) the cell compartment. Therefore, we evaluated whether blockage of Hh signaling affects expression of important fibroblast and myofibroblast genes encoding the ECM molecules, collagen-1 (Col1a1), collagen-4 (Col4a1), elastin (Eln), fibrillin (Fbn1), fibronectin (Fn1), versican (Vcan), and the cellular molecules, vimentin (Vim), Desmin (Des), Transgelin (Tagln), and a-SMA (Acta2). We also assessed mesenchymeassociated signaling pathways that are essential to lung development and for which cross-talk with Hh signaling has been reported (9), such as PDGF (Pdgfa, Pdgfra, Pdgfrb), FGF (Fgf10), connective tissue growth factor (CTGF) (Ctgf), TGF-b/bone morphogenetic protein (BMP) (Tgfb1-3, Ltbp1-4, Serpin1, Itgb6, Itgb8) and wingless-related integration site (Wnt) (axin, Lef1/Tcf7, Tcf7L2, Wif1) ( Figure E4A ). qRT-PCR analyses from total lung extracts indicate that Hh inhibition does not alter expression of most of these genes and pathways. mRNA expression levels of Col1a1, Col4a1, Eln, Fn1, and Fbn1, encoding ECM proteins that are important components of primary and secondary septa, are not decreased after Hh inhibition. However, expression of Vcan, another ECM component, is significantly reduced. Furthermore, expression of Vim and Acta2, which is important to the function of bronchial smooth muscle cells and myofibroblasts (4) , are also significantly altered in 5E1-treated lungs.
Hh Pathway Inhibition Decreases Expression of the Proteoglycan, Versican
We assessed the amount and distribution of collagen, elastin, and proteoglycans in 5E1-treated lungs. We measured total collagen-1 and elastin protein at P8 after Hh inhibition and found no significant differences ( Figure E5 ). We also performed histochemical stainings at P8 to screen for expression of collagens (Picrosirius red), elastin (Resourcin-Fuchsin), and proteoglycans (periodic acid-Schiff-Alcian blue). Although we did not observe alterations in staining intensity or distribution for collagens and elastin (data not shown), we found decreased proteoglycan staining in the septal walls and tips ( Figure 4A, a and b) .
Versican, a proteoglycan secreted by fibroblasts, is involved in lung development and tissue remodeling in lung disease (34) , and is induced by Hh signaling in the developing enteric nervous system (35) . We found that, at P8, versican is expressed in the alveolar compartment ( Figure 4A, c and d Figure 4D ), consistent with our mRNA expression data ( Figure 4B ).
Inhibition of Hh Signaling Causes a Decrease in Myofibroblasts at the Septal Tips
As both myofibroblasts and peribronchial smooth muscle cells possess the contractile cell element, a-SMA we tested whether Hh inhibition affects the numbers of a-SMA 1 cell at the septal tips or around bronchi in C57 and Gli1 nlacZ lungs. Strikingly, after Hh inhibition, there is an almost complete absence of a-SMA 1 cells at the septal tips at P6 (Figures 5B-5D ). In contrast, peribronchial a-SMA expression in cells at the septal tips, but had no gross effect on the numbers and appearance of bronchial smooth muscle cells or SPC 1 epithelial cells. These findings show that the presence of myofibroblasts at the septal tips during alveolarization is dependent upon canonical Hh signaling and indicates alteration of a cellular septum component by Hh signaling.
Inhibition of Hh Signaling Blocks Gli1
1
Cell Differentiation to Myofibroblasts
We next asked whether the absence of Gli1-expressing myofibroblasts in the alveolar septa after Hh blockage is due to loss of the Gli1 lineage-labeled cells or failure to differentiate. To track the Gli1 lineage throughout postnatal lung development, we employed the Gli1 creERT2 ;R26 tdTom reporter, which allows labeling of cells with active Hh signaling by tamoxifen-induced Cre-recombinase-mediated activation of tdTomato (tdT) expression (26) . The progeny of P1-labeled Gli1-expressing cells are detectable at P6 and P10 as tdT 1 cells in three locations: alveolar septa (including the tips), the visceral pleura, and the peribronchial smooth muscle layer ( Figures   6B and 6C) . tdT 1 cells are at the alveolar septa tips, and many are also a-SMA ;a-SMA 1 cells that we ( Figure 2C ) and others (19) We next assessed whether cells of the Gli1 lineage are present or absent in septal tips after Hh inhibition. We labeled Gli1 lineage at P1, followed by Hh inhibition at P3 ( Figure 6A) ; tdT 1 cells were present in the alveolar septal walls at P6 (Figure 6B ), equal to the IgG control ( Figure 6D ). However, there are no a-SMA 1 ;tdT 1 cells in the septa in 5E1-treated lungs. These findings indicate that the P1-labeled Gli1 lineage survives to at least P6, despite Hh inhibition at P3. They and/or their progeny persist in the septal walls, but fail to differentiate into myofibroblasts. Lung evaluation at P10 in the same experimental setup shows that tdT 1 cells are still present in the alveolar septa with Hh inhibition, but are significantly decreased in number ( Figures 6C and 6D) , possibly due to changes in proliferation or apoptosis of these cells after P6. Of note, in the same experiments, there was no effect on numbers of a-SMA
1
;tdT 1 bronchial smooth muscle cells.
Inhibition of Hh Signaling Blocks Gli1
1
Cell Proliferation
Given the proliferative and antiapoptotic properties of Hh signaling, we tested whether cell proliferation or apoptosis is affected by Hh pathway inhibition. We evaluated 5E1-treated and control lungs at P4, P5, and P6 for Ki67 expression (proliferation) and terminal deoxynucleotidyl transferase dUTP nick end labeling reactivity (apoptosis). Although there is no difference in the percentage of apoptotic cells in the alveolar compartment at P4, P5, and P6 after 5E1 treatment (data not shown), we found an approximately 30% decrease in the number of Ki67 1 cells by P6 ( Figure 7A ). To test whether Gli1 1 cells contribute to the decrease in proliferating cells, we assessed Ki67 staining in Gli1 nlacZ/1 lungs at P6. In the 5E1-blocked lungs, overall proliferation, as well as Gli1 1 cell proliferation, are decreased ( Figure 7B ). We also measured overall and 
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Gli1 lineage-specific proliferation in Gli1 creERT2 ;R26 tdTom lungs treated with tamoxifen at P1 and with 5E1 or control at P3. Again, total proliferation, as well as proliferation of tdT 1 cells, are decreased ( Figure 7C ), consistent with our lineage-tracing data showing a decrease of Gli1 lineage in 5E1-treated lungs at P10 ( Figure 6D ). These data, together with the phenotypic changes after Hh inhibition, indicate that Hh signaling provides a proliferative stimulus to the mesenchyme during alveolarization.
Discussion
In this study, we aimed to elucidate the role of Shh signaling during postnatal lung development. We established that the biphasic pattern of Hh pathway gene expression and activity parallels the temporal pattern of alveolarization (expression high) and maturation (expression low). We revealed four specific functions of Hh signaling during alveolarization with consequences on lung structure and the mesenchymal compartment: (1) Hh signaling is required for myofibroblast differentiation during growth of the secondary alveolar septa; (2) Hh signaling promotes mesenchymal proliferation, especially in the Gli1 lineage; (3) Hh signaling is required for normal versican expression; and (4) very early inhibition of Hh signaling reduces the number of new septa formed.
In this study, we show that Shh signaling affects alveolar myofibroblasts, an essential component of the growing secondary septa, where they are most prominent during alveolarization and disappear during maturation (36) . Myofibroblasts produce elastin and express contractile elements, such as a-SMA that may maintain tension of the alveolar entry rings (37) . PDGFa signaling is required for myofibroblasts during secondary septum formation (32, 33) . Other signaling pathways, such as FGF, CTGF, and TGF, also influence alveolarization; however, their link to myofibroblast function is less clear (8) . Here, we identify an additional pathway, Shh signaling, that is required for alveolar septal myofibroblast differentiation. We show that approximately 30% of alveolar cells expressing the Shh target Gli1
1 cells also coexpress a-SMA. In the absence of canonical Hh signaling, septa are almost totally devoid of a-SMA-expressing myofibroblasts. Furthermore, cells previously expressing Gli1 are not eliminated after Hh signaling is inhibited, but are unable to continue or initiate a-SMA expression, suggesting that their differentiation to myofibroblasts is blocked.
Our data demonstrating that myofibroblast differentiation in postnatal lung is regulated by Hh signaling are corroborated by several observations made by others. First, a-SMA-expressing cells are absent in Shh 2/2 lungs (38). Second, the embryonic Gli1 lineage gives rise to septal myofibroblasts in the secondary septa (19) . Third, there is a Gli consensus site within the Acta2 promoter, and Gli1-dependent Acta2 expression is inducible by Hh pathway activation (39) . Furthermore, we showed that Acta2 expression throughout the postnatal period shows a peak during alveolarization and significantly lower levels thereafter, a time course similar to the one that we observed for Hh pathway genes. Though alveolar myofibroblasts are thought to be the major source of elastin, we were unable to demonstrate decreased elastin expression in total lung RNA and protein, or altered deposition, when Hh is blocked.
It is important to reconcile our findings with what is known of PDGFa signaling in postnatal lung development. Besides the vital role of PDGFa for the process of alveolarization, studies by others suggest that both Hh and PDGFa affect fibroblasts and myofibroblasts in the growing alveolar septa. McGowan and colleagues (40) (41) proposed a gradient along the septum between Hh and PDGFa signaling that guides mesenchymal cell migration from septum base to tip. Our inhibition data suggest that Hh signaling is required for normal septal composition, and at least in part for septum initiation, independent of the PDGFa-mediated differentiation signal, in that the number of PDGFRa-expressing cells in the alveolar compartment was not decreased after Hh inhibition. The data also suggest that PDGFa pathway expression is not downstream of Hh signaling, as others have hypothesized (19) . PDGFa is present throughout embryogenesis, and therefore the lung septation defect in PDGFa knockout mice is very severe. It is not known how inhibition of PDGFa signaling in the early postnatal period would affect septum initiation and elongation. It is possible that the observed lung phenotype after Hh inhibition is due to effects of Hh signaling on other signaling pathways involved in alveolarization, such as FGF, CTGF, and TGF (8) . Our mRNA screening, however, did not show gene alterations for FGF10, CTGF, TGF, and Wnt signaling molecules. Therefore, we did not choose to explore these pathways further.
Our data provide evidence for differentiation-and proliferationpromoting roles for Shh in the postnatal lung. However, it is less clear when this particular role ends or switches to the opposite role of maintaining adult mesenchyme quiescent (42) . We observe high numbers of Gli1 1 proliferating cells during alveolarization, and a decrease in Gli1-lineage proliferation when Hh signaling is blocked. During maturation, Gli1 1 cells decrease substantially in the alveolar compartment (our data) and, at the same time, the mesenchymal space and its cell number decrease, accompanied by an apoptosis peak around P18 (5, 6). We did not find increased apoptosis when Shh signaling was inhibited during early alveolarization, suggesting that a Shh deficit alone may not account for the mesenchymal apoptosis peak that occurs during the later normal decline in Shh expression and signaling (5) .
In adult lung, we and others observe very few Gli1 1 cells in the alveolar compartment, whereas the peribronchial and perivascular pool remains prominent (21, 42, 43) . It is possible that the few residual Gli1
1 cells in the alveolar compartment are lipofibroblasts, which have been proposed as progenitors to myofibroblasts and are essential to realveolarization in adult lung (44, 45) . Our time course data for Acta2 expression, and the fact that a-SMA 1 cells in the alveolar compartment after P21 are restricted to the alveolar ducts (36) , suggest that most of the alveolar Gli1 1 cells only differentiate in the presence of Shh ligand in the clearly defined time window that we have established. In adult lung, during bleomycin injury, we showed an increase of Gli1
1
;a-SMA 1 myofibroblasts in the fibrosis regions (21) , and others demonstrated that the Gli1 lineage gives rise to these cells, consistent with the myofibroblast differentiation-promoting role of Shh. Our studies in postnatal lung, therefore, might allow us to use this knowledge when investigating the role of Shh signaling in mesenchyme in pulmonary fibrosis.
We have shown here that inhibition of Hh signaling in the postnatal period increases lung compliance. Thus, quantitative and/or qualitative aspects of lung composition (cellular or extracellular) that contribute to compliance must be altered in a way that increases compliance. We evaluated several lung components that might contribute to compliance, and identified one ECM component, the proteoglycan, versican, and one cellular component, the interstitial myofibroblast, that are dramatically altered by Hh inhibition. However, we do not yet know if either, or both, of these effects account for the change in compliance. Versican, a chondroitin-sulfate proteoglycan, is expressed by mesenchymal cells in many organs, including the lung (34) . Together with other proteoglycans, it creates hydrated gels in the alveolar septal wall interstitium in which collagen and elastin are embedded (3) . In adult lung, versican shows a patchy expression pattern in the alveolar septa, and is thought to be expressed by fibroblasts (46) . Versican is the predominantly expressed mesenchymal proteoglycan during the development of terminal sacs and alveoli in late-gestation sheep lungs (47) . High versican expression levels have also been found in human embryonic lung fibroblasts (48) and in multipotent mesenchymal stem cells during differentiation in vitro (49) . In this work, we find significant versican expression in the alveolar septa, and our co-IF data suggest that versican is at least in part produced by Gli1 1 fibroblasts. Hh inhibition decreased the number of versican 1 cells in the alveolar septa, consistent with other developmental studies in which epithelial Shh was found to induce mesenchymal versican expression (35, 50) .
In summary, we demonstrate that Shh signaling regulates mesenchyme during alveolarization by stimulating mesenchymal proliferation as well as myofibroblast differentiation and function in the growing secondary septa, thereby affecting the mechanical properties of the lung. This regulation is important for normal postnatal lung development. n Author disclosures are available with the text of this article at www.atsjournals.org.
